Jul 22, 2026
Science announces the European commercial launch of PRIMA following CE marking for patients with geographic atrophy caused by age-related macular degeneration.
The announcement separates European commercial availability from ongoing US regulatory review, bringing retinal-interface research closer to clinical use.